Retatrutide vs Tirzepatide: What the Trial Data Actually Shows
Quick answer: Retatrutide vs tirzepatide comes down to one structural difference — tirzepatide activates two hormone receptors, retatrutide activates three. In separate Phase 3 trials, retatrutide produced 28.3% average weight loss at 80 weeks and tirzepatide produced 22.5% at 72 weeks. But those are different trials with different designs, so the numbers are not directly comparable. A genuine head-to-head trial, TRIUMPH-5, is running now with results expected in 2027. Tirzepatide is approved and available today; retatrutide is not.
The Structural Difference: Two Receptors vs Three
Both drugs are made by Eli Lilly, and both belong to the incretin class. The difference is how many metabolic pathways each one engages.
Tirzepatide is a dual agonist. It activates the GLP-1 receptor, which slows gastric emptying and reduces appetite, and the GIP receptor, which modulates insulin response and fat metabolism. It is sold as Zepbound for weight management and Mounjaro for type 2 diabetes.
Retatrutide is a triple agonist. It does both of those and adds the glucagon receptor, which increases energy expenditure and hepatic fat breakdown. For the background on the drug and where its trials stand, see the full retatrutide overview.
That third receptor is the entire thesis. Tirzepatide and semaglutide work primarily by reducing how much you eat. Adding glucagon receptor activity brings the other side of the equation into play — how much energy the body burns. Whether that translates into a durable real-world advantage is precisely what TRIUMPH-5 is designed to answer.
Weight Loss Compared: The Numbers and Their Caveats
Here is the headline data from each drug’s pivotal obesity trial.
| Retatrutide (TRIUMPH-1) | Tirzepatide (SURMOUNT-1) | |
|---|---|---|
| Highest dose result | 28.3% at 12 mg | 22.5% at 15 mg |
| Mid dose | 25.9% at 9 mg | 21.4% at 10 mg |
| Low dose | 19.0% at 4 mg | 16.0% at 5 mg |
| Placebo | 2.2% | 2.4% |
| Trial duration | 80 weeks | 72 weeks |
| Participants | 2,339 | 2,539 |
| Reported | May 2026 | April 2022 |
Separate trials, not a head-to-head comparison. TRIUMPH-1 at 80 weeks; SURMOUNT-1 at 72 weeks.
Sources: Eli Lilly TRIUMPH-1 topline, May 2026; Eli Lilly SURMOUNT-1, April 2022. Both figures are efficacy estimands. Trial durations differ (80 vs 72 weeks) and populations are not matched, so this is not a head-to-head comparison. The TRIUMPH-5 trial (NCT06662383) is the direct comparison, reporting in 2027.
Why you should not read that table as a verdict
Three things make a direct comparison unreliable, and most articles comparing retatrutide vs tirzepatide skip all three.
Different durations. TRIUMPH-1 ran to 80 weeks; SURMOUNT-1’s primary endpoint was 72. Weight loss curves in this drug class were still descending at both points, so eight extra weeks is not a neutral difference.
Different estimands. Trials report results two ways. The efficacy estimand measures what happens in people who stay on the drug as directed. The treatment-regimen estimand includes everyone regardless of whether they stopped. Tirzepatide’s 22.5% is the efficacy estimand — its treatment-regimen figure at 15 mg is closer to 21%. Comparing one drug’s efficacy estimand against another’s treatment-regimen figure inflates the gap, and this happens constantly in comparison content.
Different eras and populations. SURMOUNT-1 reported in 2022, TRIUMPH-1 in 2026. Trial conduct, participant expectations, and background standard of care all shifted in between.
Semaglutide sits below both drugs on weight loss but ahead on proven cardiovascular outcomes, which changes the picture for anyone with existing heart disease — see how both compare against semaglutide.
An indirect comparison does exist. A 2025 network meta-analysis published in the Journal of the Endocrine Society pooled trials statistically and found retatrutide produced a larger absolute weight reduction than tirzepatide relative to placebo. Network meta-analysis is a legitimate method, but it is still modelling across trials rather than measuring within one.
TRIUMPH-5: The Head-to-Head Trial That Will Settle This
This is the part most comparison pages miss. Eli Lilly is running a direct comparison, and it is well underway.
| Detail | TRIUMPH-5 |
|---|---|
| Registration | NCT06662383 |
| Design | Phase 3, randomized, double-blind |
| Comparison | Retatrutide vs tirzepatide, head-to-head |
| Participants | ~800 adults with obesity |
| Duration | ~89 weeks |
| Status | Active, not recruiting |
| Primary completion | December 2026 |
| Expected results | 2027 |
Everything before 2027 is cross-trial inference. TRIUMPH-5 is the first direct measurement.
Source: ClinicalTrials.gov, NCT06662383 — A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity.
Enrolment closed before topline; how TRIUMPH-5 enrolment worked is covered with the rest of the programme. Two design features matter. It is double-blind, which removes the expectation effects that open-label trials carry. And at roughly 89 weeks it runs longer than either drug’s original pivotal trial, so it captures more of the curve rather than cutting off while weight is still falling.
There is precedent for how much these trials change the picture. When Lilly ran SURMOUNT-5 comparing tirzepatide directly against semaglutide, published in the New England Journal of Medicine in 2025, the head-to-head result confirmed what cross-trial comparisons had suggested. It does not always go that way — direct comparisons sometimes narrow gaps that looked decisive on paper — which is the reason TRIUMPH-5 matters rather than being a formality.
Side Effects: What Separates Them
Both drugs produce the gastrointestinal effects characteristic of the incretin class — nausea, vomiting, diarrhoea, constipation — concentrated during dose escalation and generally easing after.
The distinguishing signal for retatrutide is dysesthesia: abnormal skin sensations described as tingling, burning, or prickling. It is not a feature of tirzepatide’s profile, and it appears to be dose-related. In TRIUMPH-4 it occurred in 20.9% of participants at 12 mg and 8.8% at 9 mg. In TRIUMPH-1 the rate at 12 mg was lower, at 12.5%. This is the signal most likely to shape retatrutide’s eventual label and dosing guidance — see the complete side effect breakdown by dose.
On discontinuation, TRIUMPH-1 produced a result worth noting: at the 4 mg dose, participants stopped due to adverse events at 4.1%, marginally below the 4.9% placebo rate. That suggests the escalation schedule, rather than the drug itself, drives most dropouts — and that a lower-dose retatrutide could be tolerable while still delivering 19% weight loss.
Tirzepatide, by contrast, has years of post-approval real-world safety data behind it. Retatrutide has trial data only. For a drug you might take for years, that difference is substantive and does not show up in any efficacy table.
Availability, Cost, and Access in 2026
| Tirzepatide | Retatrutide | |
|---|---|---|
| FDA status | Approved | Investigational, Phase 3 |
| Brand names | Zepbound, Mounjaro | None |
| Prescription available | Yes | No |
| Insurance coverage | Varies by plan and indication | Not applicable |
| Legal access route | Prescription from a clinician | Clinical trial enrolment only |
| NDA filed | Approved 2023 (Zepbound) | Not filed as of August 2026 |
This is the gap that makes the efficacy comparison somewhat academic for now. Tirzepatide is a medication you can be prescribed this week. Retatrutide is a compound in trials — where the filing stands now is tracked separately — expected to be submitted to the FDA as a Biologics License Application in Q1 2027, with a realistic approval window in late 2027 or the first half of 2028 and availability in 2028.
Retatrutide sold online as a research peptide is not the same proposition as an approved medication — it is unregulated, unverified for purity or concentration, and outside any legal pathway for human use. The FDA issued warning letters on compounded retatrutide in September 2025.
So Which One Is Better?
The accurate answer depends on what “better” means.
On raw weight loss in trials so far, retatrutide is ahead — meaningfully, and consistently across TRIUMPH-1, TRIUMPH-4, and the Phase 2 data. The gap survives even after adjusting for the caveats above.
On evidence quality, tirzepatide wins decisively. It has approval, a published head-to-head win against semaglutide, three-year durability data showing 22.9% sustained at 176 weeks, and years of real-world use across millions of patients.
On what you can actually do about it today, there is no contest. One is prescribable, the other is not.
The honest framing is that retatrutide is the more powerful compound on current evidence and tirzepatide is the better-established one, and that TRIUMPH-5 in 2027 is what turns the first half of that sentence from a strong inference into a demonstrated fact.
For the trial-by-trial detail, safety data, and regulatory tracking behind all of the above, browse the full library of retatrutide research.
Frequently Asked Questions
Is retatrutide stronger than tirzepatide?
On the trial data available, yes — 28.3% versus 22.5% at each drug’s highest studied dose. But these come from separate trials with different durations and estimands, so the true size of the gap is not yet established. TRIUMPH-5 is the trial designed to measure it directly.
Can I switch from tirzepatide to retatrutide?
Not currently. Retatrutide is not approved and cannot be prescribed. No study has examined switching between the two, so there is no evidence base for how it would work even after approval.
Is retatrutide the same as Zepbound?
No. Zepbound is a brand name for tirzepatide, a dual GLP-1/GIP agonist. Retatrutide is a different molecule that adds glucagon receptor activity and has no brand name because it is not approved.
When will we know which is better?
TRIUMPH-5 has primary completion in December 2026, with results expected during 2027. That will be the first randomized, double-blind, direct comparison.
Does retatrutide have worse side effects than tirzepatide?
Both share the gastrointestinal profile of the incretin class. Retatrutide additionally shows dose-related dysesthesia, which tirzepatide does not. Tirzepatide has post-approval real-world safety data that retatrutide lacks entirely.
Which one is better for type 2 diabetes?
Tirzepatide is approved for type 2 diabetes as Mounjaro. Retatrutide’s Phase 3 diabetes trial, TRANSCEND-T2D-1, reported HbA1c reductions up to 1.94 percentage points at 40 weeks, but it is not approved for any indication.
Sources
- Eli Lilly. “Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.” May 21, 2026.
- Eli Lilly. “Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1.” April 28, 2022.
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387:205–216.
- Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389:514–526.
- Bajaj HS, et al. “Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1).” The Lancet. 2026.
- ClinicalTrials.gov: TRIUMPH-5, NCT06662383; TRIUMPH-1, NCT05929066; SURMOUNT-1, NCT04184622.
- Eli Lilly. SURMOUNT-1 176-week results, presented ObesityWeek 2024, published N Engl J Med.
SEO PACKAGE — DO NOT PASTE BELOW THIS LINE
Primary keyword: retatrutide vs tirzepatide
Secondary: retatrutide vs Zepbound, retatrutide vs Mounjaro, triple agonist vs dual agonist, TRIUMPH-5, is retatrutide stronger than tirzepatide, retatrutide or tirzepatide
Intent: Commercial investigation
Title tag: Retatrutide vs Tirzepatide: Full Data Comparison (2026) — 52 chars
H1: Retatrutide vs Tirzepatide: What the Trial Data Actually Shows
Meta description: Retatrutide vs tirzepatide compared on Phase 3 weight loss, side effects, and cost — plus the TRIUMPH-5 head-to-head trial reporting in 2027. — 143 chars
Slug: /retatrutide-vs-tirzepatide/
Keyword placement: primary in title tag, H1, first sentence of quick answer, one H2 (“Retatrutide vs Tirzepatide” appears in the comparison framing), and 5 further natural uses through the body. Density approximately 0.7% — deliberately under the 1–2% that triggers over-optimisation flags on YMYL.
Internal links to add:
- CLUSTER, LIVE NOW → /what-is-retatrutide/ — anchor: the full retatrutide overview — place in “The Structural Difference” section after the triple agonist paragraph
- CLUSTER, pending → /retatrutide-side-effects/ — anchor: the complete side effect breakdown by dose — place at end of dysesthesia paragraph
- CLUSTER, pending → /retatrutide-fda-approval-timeline/ — anchor: the current approval timeline — place in “Availability, Cost and Access”
- HUB → / — anchor: browse the full retatrutide research library — place at end, before FAQ
Reciprocal link to add to article 1: in /what-is-retatrutide/, cluster link 1 is currently dead anchor text reading “seeing how the three compare across mechanism, dosing, and cost”. Wrap it in <a href="/retatrutide-vs-tirzepatide/"> now that this page exists.
Correction to article 1: the comparison table footnote says no head-to-head trial exists. Update to name TRIUMPH-5 and its 2027 readout — it strengthens the page and links naturally here.